Table 3.
Susceptibilities of Pseudomonas aeruginosa for All Regions and Time Periods
| CLSIa | EUCASTa | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Resistant Phenotype Antimicrobial Agent | MIC50b (mg/L) | MIC90 (mg/L) | Range (mg/L) | %S | %I | %R | %S | %I | %R |
| All isolates (52 022) | |||||||||
| Amikacin | ≤4 | 16 | ≤4 to >32 | 90.5 | 2.5 | 7 | 86.0 | 4.5 | 9.5 |
| Aztreonam | 8 | >16 | ≤0.12 to >16 | 64.7 | 13.8 | 21.5 | 4.6 | 73.9 | 21.5 |
| Cefepime | 4 | 16 | ≤0.5 to >16 | 79.3 | 10.9 | 9.8 | 79.3 | 20.7 | |
| Ceftazidime | ≤2 | >16 | ≤2 to >16 | 77.5 | 5.2 | 17.3 | 77.5 | 22.5 | |
| Ciprofloxacin | ≤0.5 | >2 | ≤0.5 to >2 | 73 | 4.5 | 22.6 | 67.8 | 32.2 | |
| Colistin | 1 | 2 | ≤0.5 to >4 | 99.4 | 0.6 | 99.4 | 0.6 | ||
| Meropenem | 0.5 | >8 | ≤0.12 to >8 | 76.1 | 6.5 | 17.4 | 76.1 | 13 | 10.9 |
| Piperacillin-tazobactam | 8 | >64 | ≤1 to >64 | 73.2 | 12.1 | 14.8 | 73.2 | 26.8 | |
| Tobramycin | 0.5 | >8 | ≤0.25 to >8 | 84.6 | 0.9 | 14.5 | 84.6 | 15.4 | |
| Multidrug resistant (12 972) | |||||||||
| Amikacin | 8 | >32 | ≤4 to >32 | 65.0 | 8.6 | 26.4 | 52.7 | 12.3 | 35 |
| Aztreonam | >16 | >16 | ≤0.12 to >16 | 15.6 | 22.1 | 62.3 | 1.1 | 36.7 | 62.3 |
| Cefepime | 16 | >16 | ≤0.12 to >16 | 26.8 | 36.5 | 36.7 | 26.8 | 73.2 | |
| Ceftazidime | >16 | >16 | ≤2 to >16 | 26.3 | 14.9 | 58.8 | 26.3 | 73.7 | |
| Ciprofloxacin | >2 | >2 | ≤0.5 to >2 | 24.6 | 7.5 | 67.9 | 17.1 | 82.9 | |
| Colistin | 1 | 2 | ≤0.5 to >4 | 98.9 | 1.1 | 98.9 | 1.1 | ||
| Meropenem | 8 | >8 | ≤0.12 to >8 | 27.5 | 13.4 | 59.1 | 27.5 | 32.1 | 40.4 |
| Piperacillin-tazobactam | >64 | >64 | ≤0.5 to >64 | 13.8 | 34.7 | 51.4 | 13.8 | 86.2 | |
| Tobramycin | >8 | >8 | ≤0.25 to >8 | 45.7 | 2.8 | 51.5 | 45.7 | 54.3 | |
| Extensively drug resistant (9161) | |||||||||
| Amikacin | 16 | >32 | ≤4 to >32 | 55.9 | 10.3 | 33.8 | 42.6 | 13.3 | 44.1 |
| Aztreonam | >16 | >16 | ≤0.12 to >16 | 12 | 21.6 | 66.4 | 0.5 | 33.1 | 66.4 |
| Cefepime | 16 | >16 | ≤0.12 to >16 | 14.2 | 39.4 | 46.3 | 14.2 | 85.8 | |
| Ceftazidime | >16 | >16 | ≤2 to >16 | 16.2 | 15.6 | 68.2 | 16.2 | 83.8 | |
| Ciprofloxacin | >2 | >2 | ≤0.5 to >2 | 13.6 | 7.3 | 79.2 | 7.8 | 92.2 | |
| Colistin | 1 | 2 | ≤0.5 to >4 | 98.7 | 1.3 | 98.7 | 1.3 | ||
| Meropenem | >8 | >8 | ≤0.12 to >8 | 17.6 | 12.4 | 70 | 17.6 | 31.7 | 50.7 |
| Piperacillin-tazobactam | >64 | >64 | ≤0.5 to >64 | 5.5 | 34.7 | 59.8 | 5.5 | 94.5 | |
| Tobramycin | >8 | >8 | ≤0.25 to >8 | 34.2 | 3.0 | 62.9 | 34.2 | 65.8 | |
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing.
aCriteria as published by CLSI 2018 and EUCAST 2018.
bMIC, minimum inhibitory concentration; S, susceptible, I, intermediate, R, resistant.